These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33412170)

  • 1. The potential therapeutic effect of adipose-derived mesenchymal stem cells in the treatment of cutaneous leishmaniasis caused by L. major in BALB/c mice.
    Bahrami S; Safari M; Razi Jalali MH; Ghorbanpoor M; Tabandeh MR; Rezaie A
    Exp Parasitol; 2021 Mar; 222():108063. PubMed ID: 33412170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
    Ramos TD; Silva JD; da Fonseca-Martins AM; da Silveira Pratti JE; Firmino-Cruz L; Maciel-Oliveira D; Dos-Santos JS; Tenorio JIN; de Araujo AF; Freire-de-Lima CG; Diaz BL; Cruz FF; Rocco PRM; de Matos Guedes HL
    Stem Cell Res Ther; 2020 Aug; 11(1):374. PubMed ID: 32867857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated intravenous injection of adipose tissue derived mesenchymal stem cells enhances Th1 immune responses in Leishmania major-infected BALB/c mice.
    Zanganeh E; Soudi S; Zavaran Hosseini A; Khosrojerdi A
    Immunol Lett; 2019 Dec; 216():97-105. PubMed ID: 31622634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major.
    Navard SH; Rezvan H; Haddad MHF; Ali SA; Nourian A; Eslaminejad MB; Behmanesh MA
    J Glob Antimicrob Resist; 2020 Dec; 23():243-250. PubMed ID: 32977079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral treatment with zinc sulfate increases the expression of Th1 cytokines mRNA in BALB/c mice infected with Leishmania major.
    Afshari M; Riazi-Rad F; Khaze V; Bahrami F; Ajdary S; Alimohammadian MH
    Cytokine; 2016 May; 81():71-6. PubMed ID: 26896749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against Leishmania major-infected BALB/c mice.
    Montakhab-Yeganeh H; Abdossamadi Z; Zahedifard F; Taslimi Y; Badirzadeh A; Saljoughian N; Taheri T; Taghikhani M; Rafati S
    Parasite Immunol; 2017 Oct; 39(10):. PubMed ID: 28833211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-exposure with low-dose UVA suppresses lesion development and enhances Th1 response in BALB/c mice infected with Leishmania (Leishmania) amazonensis.
    Khaskhely NM; Maruno M; Takamiyagi A; Uezato H; Kasem KM; Hosokawa A; Kariya K; Hashiguchi Y; Landires EA; Nonaka S
    J Dermatol Sci; 2001 Jul; 26(3):217-32. PubMed ID: 11390207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cells alter macrophage immune responses to Leishmania major infection in both susceptible and resistance mice.
    Dameshghi S; Zavaran-Hosseini A; Soudi S; Shirazi FJ; Nojehdehi S; Hashemi SM
    Immunol Lett; 2016 Feb; 170():15-26. PubMed ID: 26703818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileishmanial activity of Urtica dioica extract against zoonotic cutaneous leishmaniasis.
    Badirzadeh A; Heidari-Kharaji M; Fallah-Omrani V; Dabiri H; Araghi A; Salimi Chirani A
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007843. PubMed ID: 31929528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmanicidal potentials of
    Sharifi F; Sharififar F; Pournamdari M; Ansari M; Tavakoli Oliaee R; Bamorovat M; Khosravi A; Keyhani AR; Salarkia E; Mortazaeizdeh A; Dabiri S; Khamesipour A; Sharifi I
    J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34115583
    [No Abstract]   [Full Text] [Related]  

  • 11. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain.
    Alleva DG; Kaser SB; Beller DI
    J Immunol; 1998 Dec; 161(12):6878-84. PubMed ID: 9862720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
    von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
    Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of TLRs 2, 4, 9, iNOS and TNF-α and arginase activity in peripheral blood monocytes from glucantime unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis caused by Leishmania tropica.
    Oliaee RT; Sharifi I; Afgar A; Jafarzadeh A; Kareshk AT; Bamorovat M; Sharifi H; Babaei Z; Keyhani A; Keyhani A; Abedi L; Sharifi F
    Microb Pathog; 2019 Jan; 126():368-378. PubMed ID: 30399441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice.
    Uzonna JE; Bretscher PA
    Eur J Immunol; 2001 Nov; 31(11):3175-84. PubMed ID: 11745334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.
    Radwanska M; Cutler AJ; Hoving JC; Magez S; Holscher C; Bohms A; Arendse B; Kirsch R; Hunig T; Alexander J; Kaye P; Brombacher F
    PLoS Pathog; 2007 May; 3(5):e68. PubMed ID: 17500591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
    Skeiky YA; Guderian JA; Benson DR; Bacelar O; Carvalho EM; Kubin M; Badaro R; Trinchieri G; Reed SG
    J Exp Med; 1995 Apr; 181(4):1527-37. PubMed ID: 7699334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of negative air ions (NAIs) on Leishmania major: A novel tool for treatment of zoonotic cutaneous leishmaniasis (ZCL).
    Badirzadeh A; Najm M; Hemphill A; Alipour M; Hasanpour H; Masoori L; Karimi P
    PLoS One; 2022; 17(9):e0274124. PubMed ID: 36074764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phlebotomus papatasi sand fly salivary gland lysate down-regulates a Th1, but up-regulates a Th2, response in mice infected with Leishmania major.
    Mbow ML; Bleyenberg JA; Hall LR; Titus RG
    J Immunol; 1998 Nov; 161(10):5571-7. PubMed ID: 9820534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipose-Derived Stem Cells' Secretome Attenuates Lesion Size and Parasite Loading in Leishmaniasis Caused by
    Khodkar I; Saki J; Arjmand R; Saki G; Khorsandi L
    Iran J Med Sci; 2024 Feb; 49(2):121-129. PubMed ID: 38356483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.